Interleukin-1 in COVID-19 Infection: Immunopathogenesis and Possible Therapeutic Perspective
… In addition, the IL-1 cytokine family has a pivotal role in the induction of cytokine storm due
… COVID-19 infection. This article reviews the role of IL-1 in inflammation and utilization of IL-1 …
… COVID-19 infection. This article reviews the role of IL-1 in inflammation and utilization of IL-1 …
Interleukin‐1 blocking agents for treating COVID‐19
Cochrane Emergency and Critical Care … - Cochrane Database …, 1996 - cochranelibrary.com
… ‐1 blocking agents compared with standard care alone or with placebo on effectiveness and
safety outcomes in people with COVID‐19. … on the COVID‐NMA platform ( covid-nma.com) . …
safety outcomes in people with COVID‐19. … on the COVID‐NMA platform ( covid-nma.com) . …
NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis
N Potere, E Garrad, Y Kanthi, M Di Nisio… - Cardiovascular …, 2023 - academic.oup.com
… We herein outline the contribution of immunothrombosis to COVID-19-… of COVID-19. We
also summarize current efforts to target the NLRP3 inflammasome pathway in COVID-19, and …
also summarize current efforts to target the NLRP3 inflammasome pathway in COVID-19, and …
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
… Mortality of patients with coronavirus disease 2019 (COVID-19), … Anakinra is a recombinant
interleukin-1 receptor antagonist … This study is part of the COVID-19 Biobank study, which is …
interleukin-1 receptor antagonist … This study is part of the COVID-19 Biobank study, which is …
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
… differences in global outcomes of COVID-19 patients treated with IL-1 versus IL-6 … COVID-19
as well as the design of controlled investigations evaluating cytokine inhibitors in COVID-19…
as well as the design of controlled investigations evaluating cytokine inhibitors in COVID-19…
Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
… coronavirus 2 (SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus
disease 2019 (COVID-19… Evidence suggests that inflammasome activation and interleukin-1β (IL…
disease 2019 (COVID-19… Evidence suggests that inflammasome activation and interleukin-1β (IL…
Specific interleukin-1 inhibitors, specific interleukin-6 inhibitors, and GM-CSF blockades for COVID-19 (at the edge of sepsis): a systematic review
Y Wang, K Zhu, R Dai, R Li, M Li, X Lv… - Frontiers in …, 2022 - frontiersin.org
… ), some severe and critically ill COVID-19 patients with multiple organ … specific interleukin
(IL)-1 inhibitors, specific IL-6 inhibitors, and GM-CSF blockades in the treatment of COVID-19 (…
(IL)-1 inhibitors, specific IL-6 inhibitors, and GM-CSF blockades in the treatment of COVID-19 (…
[HTML][HTML] Genetic variation of interleukin-1 receptor type 1 is associated with severity of COVID-19 disease
R Wang - The Journal of Infection, 2022 - ncbi.nlm.nih.gov
… IL-1 family are central mediators of the COVID-19 cytokine storm. Thus, we aim to explore
whether a genetic variation of the IL-1 family is associated with COVID-19. The acronym IL-1 …
whether a genetic variation of the IL-1 family is associated with COVID-19. The acronym IL-1 …
The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical)
M Ghofrani Nezhad, G Jami, O Kooshkaki… - Journal of Interferon & …, 2023 - liebertpub.com
… are an independent predictor of COVID-19 illness because they were significantly … COVID-19
symptoms. Anakinra and tocilizumab (TCZ) are beneficial in lowing mortality in COVID-19 …
symptoms. Anakinra and tocilizumab (TCZ) are beneficial in lowing mortality in COVID-19 …
[HTML][HTML] Interleukin‐1 blockade with anakinra in acute leukaemia patients with severe COVID‐19 pneumonia appears safe and may result in clinical improvement
JW Day, TA Fox, R Halsey, B Carpenter… - British Journal of …, 2020 - ncbi.nlm.nih.gov
… by coronavirus disease 2019 (COVID‐19) worldwide has exceeded 4·5 million. A subgroup
of patients with COVID‐19 … COVID‐19 and are currently being investigated in clinical trials. …
of patients with COVID‐19 … COVID‐19 and are currently being investigated in clinical trials. …
相关搜索
- covid 19 interleukin 1 blockade
- patients with covid 19 interleukin 1
- pathogenesis of covid 19 interleukin 6
- forms of covid 19 interleukin 6
- covid 19 interleukin 6 antagonists
- covid 19 meta analysis
- severe covid 19 pneumonia
- covid 19 acute leukemia
- covid 19 nlrp3 inflammasome
- covid 19 infection
- covid 19 effect of anakinra
- covid 19 sars cov
- covid 19 role of il 6
- interleukin 6 inhibitors non-covid 19 ards
- covid 19 systematic review
- covid 19 cohort study